OpenAI introduces model to enhance research in longevity
A research organization has teamed up with a startup focused on improving stem cell production. Read Full Article at RT.com.
TroibNews 
A research organization has teamed up with a startup to explore methods for enhancing stem cell production.
OpenAI has introduced a new language model named GPT-4b micro, which is tailored to assist scientists in extending human lifespan, according to MIT Technology Review. This prominent artificial intelligence research body has partnered with a company called Retro Biosciences in a venture aimed at refining stem cell production through the re-engineering of select proteins.
Stem cells are vital in regenerative medicine because of their capacity to transform into various cell types, which holds promise for treatments targeting age-related ailments.
Founded in 2021, Retro Biosciences is a startup dedicated to increasing human lifespan through cellular reprogramming. In 2022, OpenAI CEO Sam Altman made a significant investment of $180 million in the company.
The GPT-4b micro model investigates ways to alter Yamanaka factors, which are proteins that can convert adult cells into stem cells. Initial experiments have shown that the proteins modified by the model are over 50 times more effective at inducing stem cell production compared to their natural versions.
The model's training utilized extensive biological data from a wide array of species, allowing it to predict protein structures and interactions with greater accuracy than conventional approaches.
In a recent article, MIT Technology Review quoted OpenAI developer John Hallman, who noted, “just across the board, the proteins seem better than what the scientists were able to produce by themselves.”
Currently, GPT-4b micro is in its research phase and is not available for public use. OpenAI intends to publish its findings for peer review in the future.
Another developer involved in the project, Aaron Jaech, mentioned to MIT Technology Review that the initiative aims to solidify OpenAI's role in scientific research. He also stated that it remains too early to determine “whether those capabilities will come out to the world as a separate model or whether they’ll be rolled into our mainline reasoning models.”
In 2018, Google launched the first version of AlphaFold, an AI model designed to decipher the complex 3D structures of proteins. According to Google DeepMind, AlphaFold can accomplish this task within minutes “to a remarkable degree of accuracy.”
While working in a similar domain, GPT-4b micro employs different principles that assist researchers in effectively re-engineering specific proteins.
In recent years, numerous research teams globally have utilized AI in the pursuit of developing innovative therapies. A study published in the scientific journal Nature this past Wednesday indicated that AI-designed proteins could neutralize deadly snake venom.
In 2022, researchers from the University of Washington School of Medicine and Harvard University announced their success in training several image-generating AI models to create new proteins with potential applications in vaccines and cancer treatments, among other fields.
David Baker, a professor of biochemistry at UW Medicine and senior author of the study, remarked at the time, “The proteins we find in nature are amazing molecules, but designed proteins can do so much more.” He was subsequently awarded the 2024 Nobel Prize in Chemistry for his work in computational protein design.
Thomas Evans for TROIB News
OpenAI has introduced a new language model named GPT-4b micro, which is tailored to assist scientists in extending human lifespan, according to MIT Technology Review. This prominent artificial intelligence research body has partnered with a company called Retro Biosciences in a venture aimed at refining stem cell production through the re-engineering of select proteins.
Stem cells are vital in regenerative medicine because of their capacity to transform into various cell types, which holds promise for treatments targeting age-related ailments.
Founded in 2021, Retro Biosciences is a startup dedicated to increasing human lifespan through cellular reprogramming. In 2022, OpenAI CEO Sam Altman made a significant investment of $180 million in the company.
The GPT-4b micro model investigates ways to alter Yamanaka factors, which are proteins that can convert adult cells into stem cells. Initial experiments have shown that the proteins modified by the model are over 50 times more effective at inducing stem cell production compared to their natural versions.
The model's training utilized extensive biological data from a wide array of species, allowing it to predict protein structures and interactions with greater accuracy than conventional approaches.
In a recent article, MIT Technology Review quoted OpenAI developer John Hallman, who noted, “just across the board, the proteins seem better than what the scientists were able to produce by themselves.”
Currently, GPT-4b micro is in its research phase and is not available for public use. OpenAI intends to publish its findings for peer review in the future.
Another developer involved in the project, Aaron Jaech, mentioned to MIT Technology Review that the initiative aims to solidify OpenAI's role in scientific research. He also stated that it remains too early to determine “whether those capabilities will come out to the world as a separate model or whether they’ll be rolled into our mainline reasoning models.”
In 2018, Google launched the first version of AlphaFold, an AI model designed to decipher the complex 3D structures of proteins. According to Google DeepMind, AlphaFold can accomplish this task within minutes “to a remarkable degree of accuracy.”
While working in a similar domain, GPT-4b micro employs different principles that assist researchers in effectively re-engineering specific proteins.
In recent years, numerous research teams globally have utilized AI in the pursuit of developing innovative therapies. A study published in the scientific journal Nature this past Wednesday indicated that AI-designed proteins could neutralize deadly snake venom.
In 2022, researchers from the University of Washington School of Medicine and Harvard University announced their success in training several image-generating AI models to create new proteins with potential applications in vaccines and cancer treatments, among other fields.
David Baker, a professor of biochemistry at UW Medicine and senior author of the study, remarked at the time, “The proteins we find in nature are amazing molecules, but designed proteins can do so much more.” He was subsequently awarded the 2024 Nobel Prize in Chemistry for his work in computational protein design.
Thomas Evans for TROIB News
